Graphen Drugomics
Transforming Drug Discovery with AI Precision
Millions Wait for a Cure That May Never Come
Every day, millions of rare disease patients wake up knowing there’s no treatment available for them. Drug companies hesitate to invest because the market is ‘too small’. But to the families affected, every second counts.
0+
Rare Diseases Identified
0M
People Impact Worldwide
<0%
Have FDA-Approved Treatment
Our mission is to revolutionize drug discovery with AI, ensuring that no disease—no matter how rare—goes untreated.
The Harsh Reality:
- Prolong Development - Many patients spend years searching for answers.
- Lack of Effective Treatments - Fewer than 5% of rare diseases have approved drugs.
- Cost Gaps - Traditional pharmaceutical companies often overlook low-market diseases.
The Solution? AI-Driven Solutions for Human Diseases
Additionally, millions of patients with chronic diseases lack optimal care due to the conventional 'one-size-fits-all' approach to drug development, which overlooks genetic variations that influence treatment responses.
At Graphen Drugomics, we believe that no disease should be too rare to treat. Using AI-driven precision medicine, we accelerate drug development for rare diseases, making life-saving treatments possible.
Why Invest & Partner in AI Drug Discovery?
A Faster, Smarter Path to Breakthrough Medicines
0x
Faster Drug Discovery
Developing a single drug traditionally takes up to 10 years, but with Graphen’s AI, we generate 2-3 drug candidates per month, accelerating the process by over 27 times.
0x
Higher Success Rates
AI boosts success rates beyond 90%, outperforming traditional drug development.
0%
Cost Reduction
AI enables us to develop 1,335 drugs for the cost of one traditional drug.
Meet Atom: AI Tools for Medicine
Graphen Drugomics' Atom platform comprises a suite of AI-driven tools designed to accelerate the drug discovery process. From analyzing omics data to developing precision therapies, Atom provides a comprehensive solution for modern drug design.
Atom Network
- Quantum Physics
- Dynamic Graphs
Learn More
Protein Structure
- Protein Sequence
- Equivalent Graph
Learn More
Protein Function
- Biological Process
- Molecular Function
Learn More
Molecular Interaction
- Reaction Simulation
- Energy Score
Learn More
Affinity Prediction
- Energy Change
- Affinity Score
Learn More
Biology Networks
- Protein Networks
- Pathway Networks
Learn More
ADME Prediction
- Drug Pharmacokinetics
- ADME Score
Learn More
Antibody Developability
- Antibody PDB
- TAP Score
Learn More
Drug Generation
- Multi-Goals
- Specific Target
Learn More
Mutation Intelligence
- Virus & Human Genome
- Function Prediction
Learn More
Progress Prediction
- Disease Progress
- Drug Resistence
Learn More
Multi-Omics Analytics
- Cross-Omics Networks
- Single-Cell Analytics
Learn More
From AI to Breakthrough Medicines: Our Drug Discovery Pipeline
Harnessing AI to accelerate drug discovery and advance candidates from target identification to clinical trials.
Rare Disease Pipeline
Disease Area
TARGET ID
IN-VITRO VERFICATION
ANIMAL POC
PRECLINICAL/IND READY
CLINICAL
Triple Negative Breast Cancer (TNBC)
Acute myeloid leukemia (AML)
Muscular Dystrophy
Neuroblastoma
Common Disease Pipeline
Disease Area
TARGET ID
IN-VITRO VERFICATION
ANIMAL POC
PRECLINICAL/IND READY
CLINICAL
Osteoarthritis (OA)
Fibrotic Disorders
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Addiction-Related Disorder
Auto-Immune Disease
Meet the Experts - Driving AI Drug Discovery
Dr. Ching-Yung Lin
CEO at Graphen
A pioneer in Network Science and Artificial Intelligence.
Dr. Chiao Wen Chen
CTO and Taiwan GM, Graphen Druogmics
20+ years of experience in preclinical drug development.
Dr. Nathan Chen
Chief Strategy Officer, Graphen Drugomics
Guru in the Pharmaceutical Industry
Mr. KinWei Soh
BD, Graphen Singapore
Ex-Director at Pfizer Singapore and at Pfizer China for Business Solutions.
Mr. Tom Wang
Chief Operating Officer, Graphen Asia
Successful recursive entrepreneur.
Dr. Richard Liang
Director, Translational Medicine, Graphen Drugomics
Mr. Yi Ting Chen
Director, AI Platform, Graphen Drugomics
Has years of experience in drug development
Dr. John Huang
Director, Drug Development, Graphen Drugomics.
Expertise in systems biology and AI bioinformatics.
Latest Insights and Industry Trends
Ready to elevate your business?
Join Us in Shaping the Future of Innovation!
Contact Graphen to explore transformative solutions and collaborative opportunities.
2025 Graphen Inc. All rights reserved.